Table 1 Clinical Characterization of the cohortsâ€
| Â | Â | Cohort #1 | Cohort #2 | |||
|---|---|---|---|---|---|---|
| Â | Â | TSCC | Normal | TSCC | Premalignant | Normal |
Age | Median (range) | 57 (32-82) | 56 (37-78) | 53 (21-77) | 51 (30-82) | 47 (30-72) |
Gender | Male: n (%) | 39 (73.58) | 13 (59.09) | 60 (60.00) | 17 (54.84) | 6 (40.00) |
| Â | Female: n (%) | 14 (26.42) | 9 (40.91) | 40 (40.00) | 14 (45.16) | 9 (60.00) |
T stage | Stage 4: n (%) | 30 (56.60) | Â | 6 (6.00) | Â | Â |
| Â | Stage 3: n (%) | 4 (7.55) | Â | 15 (15.00) | Â | Â |
| Â | Stage 2: n (%) | 12 (22.64) | Â | 51 (51.00) | Â | Â |
| Â | Stage 1: n (%) | 7 (13.21) | Â | 28 (28.00) | Â | Â |
N stage (Pathological) | Stage 2: n (%) | 23 (43.40) | Â | 18 (18.00) | Â | Â |
| Â | Stage 1: n (%) | 4 (7.55) | Â | 22 (22.00) | Â | Â |
| Â | Stage 0: n (%) | 26 (49.05) | Â | 60 (60.00) | Â | Â |
Clinical stage | Stage 4: n (%) | 39 (73.58) | Â | 21 (21.00) | Â | Â |
| Â | Stage 3: n (%) | 4 (7.55) | Â | 27 (27.00) | Â | Â |
| Â | Stage 2: n (%) | 7 (13.21) | Â | 26 (26.00) | Â | Â |
| Â | Stage 1: n (%) | 3 (5.66) | Â | 26 (26.00) | Â | Â |
Grade ‡ | Well: n (%) | NA |  | 51 (51.00) |  |  |
| Â | Mod: n (%) | NA | Â | 30 (30.00) | Â | Â |
| Â | Poor: n (%) | NA | Â | 19 (19.00) | Â | Â |